(Q37737327)

22 August 2017

1 reference

title

Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment (English)

1 reference

22 August 2017

Morten Frier Gjerstorff

series ordinal

1

1 reference

22 August 2017

Jorge Burns

series ordinal

2

1 reference

22 August 2017

Henrik Jorn Ditzel

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

1 reference

22 August 2017

10

1 reference

22 August 2017

1061-1075

1 reference

22 August 2017

7

1 reference

Cancer/testis antigens, gametogenesis and cancer

22 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

The testis in immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Cancer/testis antigens: structural and immunobiological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Tumor-specific shared antigenic peptides recognized by human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Rapid evolution of cancer/testis genes on the X chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Genome-wide analysis of cancer/testis gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Expression of GAGE family proteins in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Molecular mechanisms underlying human synovial sarcoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Detection of MAGE-A transcripts in bone marrow is an independent prognostic factor in operable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Concise review: cancer/testis antigens, stem cells, and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

DNA methylation-associated repression of cancer-germline genes in human embryonic and adult stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Epigenetic modulation of cancer-germline antigen gene expression in tumorigenic human mesenchymal stem cells: implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Fertilin beta and other ADAMs as integrin ligands: insights into cell adhesion and fertilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

MAGE Xp-2: a member of the MAGE gene family isolated from an expression library using systemic lupus erythematosus sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

NY-ESO-1: review of an immunogenic tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Expression of MAGE genes in primary and metastatic cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Heat shock protein 70 / MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

The use of filamentous bacteriophage fd to deliver MAGE-A10 or MAGE-A3 HLA-A2-restricted peptides and to induce strong antitumor CTL responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Tumor-reactive CD8+ T-cell clones in patients after NY-ESO-1 peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Update on anti-CTLA-4 antibodies in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Promoter-dependent mechanism leading to selective hypomethylation within the 5' region of gene MAGE-A1 in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Characterization and expression of CT45 in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Methylation-regulated expression of HLA class I antigens in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Acetylation-induced transcription is required for active DNA demethylation in methylation-silenced genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

HDAC inhibitor-based therapies and haematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Deacetylase inhibition promotes the generation and function of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Heterogeneity of embryonic and adult stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Dynamic equilibrium and heterogeneity of mouse pluripotent stem cells with distinct functional and epigenetic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Autoimmunogenicity of the human sperm protein Sp17 in vasectomized men and identification of linear B cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.485188

10.1517/14712598.2010.485188

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference